Emisphere Highlights Positive Phase 2 OG217SC Data From Eligen(R) Licensee Novo Nordisk

20. February 2015

Sustainable Alternatives to Petroleum-Derived Excipients in Pharmaceutical Oil-in-Water Creams

Investigating the Effectiveness of Different Porous Nanoparticles as Drug Carriers for Retaining the Photostability of Pinosylvin Derivative

Design of a Novel Delivery Efficiency Feedback System for Biphasic Dissolving Microarray Patches Based on Poly(Lactic Acid) and Moisture-Indicating Silica

ROSELAND, N.J., Feb. 20, 2015 (GLOBE NEWSWIRE) — Emisphere Technologies, Inc. (OTCBB:EMIS) today highlighted positive Phase 2 data from Eligen® licensee Novo Nordisk pertaining to OG217SC, the oral formulation of semaglutide, a long-acting human GLP-1 analogue that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. OG217SC is provided in a tablet formulation with an absorption-enhancing excipient, SNAC. SNAC is included in the Eligen® Carrier Concept.